Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | CES2 | O00748 | 4/20 | 0.42 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28831109 | 0.92 | THRA (0.37) | ESR1MEN1KMT2A | |
| SCHEMBL28831189 | 0.83 | HDAC3 (0.42) | CES2CES1ALDH1A1MEN1KMT2A | |
| SCHEMBL1661857 | 0.83 | HTR7 (0.49) | PTGS2ALDH1A1 | |
| SCHEMBL28831250 | 0.83 | LMNA (0.45) | ESR1ALDH1A1 | |
| SCHEMBL1661832 | 0.82 | MAOB (0.52) | PTGS2ALDH1A1 | |
| SCHEMBL28831256 | 0.81 | KMT2A (0.42) | KMT2A | |
| SCHEMBL28831198 | 0.81 | HDAC1 (0.48) | CES2CES1ALDH1A1MEN1KMT2A | |
| SCHEMBL28831180 | 0.80 | TAS1R3 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL28831274 | 0.80 | HDAC1 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL28831173 | 0.80 | NR1I2 (0.47) | PTGS2CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853804-B | Method for synthesizing high-regioselectivity alpha-alkenyl stannane by hydrogenating terminal alkyne stannum marshi | 浙江大学 | 2024-07-05 | — | — | CN | disclosed |
| CN-114853804-A | Method for synthesizing high-regioselectivity alpha-alkenyl stannane by hydrogenation of terminal alkyne martensitic tin | 浙江大学 | 2022-08-05 | — | — | CN | disclosed |
| EP-1592698-B1 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | US | disclosed |
| US-7129367-B2 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-16 | — | — | US | disclosed |
| WO-2003061385-A1 | TRICYCLIC NUCLEOSIDE LIBRARY COMPOUNDS, SYNTHESIS, AND USE AS ANTIVIRAL AGENTS | RIBAPHARM INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003061576-A2 | DEAZAPURINE NUCLEOSIDE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS | RIBAPHARM INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062257-A1 | DEAZAPURINE NUCLEOSIDE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS | RIBAPHARM INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003051897-A1 | NUCLEOSIDE ANALOG LIBRARIES AND COMPOUNDS | RIBAPHARM INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051896-A1 | CYTIDINE LIBRARIES AND COMPOUNDS SYNTHESIZED BY SOLID-PHASE COMBINATORIAL STRATEGIES | RIBAPHARM INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051899-A1 | DEAZAPURINE NUCLEOSIDE LIBRARIES AND COMPOUNDS | RIBAPHARM INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051898-A1 | UNUSUAL NUCLEOSIDE LIBRARIES, COMPOUNDS, AND PREFERRED USES AS ANTIVIRAL AND ANTICANCER AGENTS | RIBAPHARM INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051881-A1 | SUBSTITUTED PURINE NUCLEOSIDE LIBRARIES AND COMPOUNDS BY SOLID-PHASE COMBINATORIAL STRATEGIES | RIBAPHARM INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | SQLE, C9, PHOSPHO1 | PTGS2 3253/4885CES2 3828/4885CES1 3108/4885 |
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | GPR119, IDO2, IDO1 | PTGS2 591/4885CES2 1480/4885CES1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.